Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 20, 2008

GSK Makes Cancer Cell Genomic Data Available on caBIG

  • GlaxoSmithKline has  released genomic profiling data for over 300 cancer cell lines via the NCI’s cancer Bioinformatics Grid™ (caBIG™).

    The genomic data being shared by GSK through caBIG come from cell lines derived from a wide variety of tumors, including breast, prostate, lung, and ovarian cancers.

    The NCI launched the caBIG initiative in 2004 to accelerate the research and discovery of new approaches to the detection, diagnosis, treatment, and prevention of cancer. Since that time, more than 200 organizations and 1,000 individuals have helped to create more than 40 biomedical research tools such as caArray, the microarray data-management system that is guiding the annotation and supporting the exchange of the cancer cell array data provided by GSK.

    Related Links:

    Biobanking Emerging as a Key Growth Area

    Uniting Efforts in Molecular Medicine

    Evaluating Data Flow in Systems Biology

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »